CureVac (CVAC) Competitors $3.27 +0.08 (+2.51%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. XENE, IBRX, AMRX, MLTX, TWST, HCM, MIRM, VCEL, BHC, and BHVNShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), MoonLake Immunotherapeutics (MLTX), Twist Bioscience (TWST), HUTCHMED (HCM), Mirum Pharmaceuticals (MIRM), Vericel (VCEL), Bausch Health Companies (BHC), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Xenon Pharmaceuticals ImmunityBio Amneal Pharmaceuticals MoonLake Immunotherapeutics Twist Bioscience HUTCHMED Mirum Pharmaceuticals Vericel Bausch Health Companies Biohaven Xenon Pharmaceuticals (NASDAQ:XENE) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Which has more risk and volatility, XENE or CVAC? Xenon Pharmaceuticals has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.48, suggesting that its share price is 148% more volatile than the S&P 500. Which has preferable valuation and earnings, XENE or CVAC? Xenon Pharmaceuticals has higher earnings, but lower revenue than CureVac. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M254.87-$182.39M-$3.02-10.40CureVac$543.28M1.31-$281.58M$0.555.80 Does the MarketBeat Community believe in XENE or CVAC? Xenon Pharmaceuticals received 397 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 69.92% of users gave Xenon Pharmaceuticals an outperform vote while only 55.32% of users gave CureVac an outperform vote. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes42369.92% Underperform Votes18230.08% CureVacOutperform Votes2655.32% Underperform Votes2144.68% Does the media prefer XENE or CVAC? In the previous week, CureVac had 14 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 23 mentions for CureVac and 9 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.10 beat CureVac's score of 0.37 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive CureVac 4 Very Positive mention(s) 6 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is XENE or CVAC more profitable? CureVac has a net margin of 20.72% compared to Xenon Pharmaceuticals' net margin of 0.00%. CureVac's return on equity of 21.98% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.69% -23.68% CureVac 20.72%21.98%15.72% Do insiders and institutionals have more ownership in XENE or CVAC? 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend XENE or CVAC? Xenon Pharmaceuticals presently has a consensus price target of $57.38, indicating a potential upside of 82.72%. CureVac has a consensus price target of $10.00, indicating a potential upside of 213.48%. Given CureVac's higher possible upside, analysts clearly believe CureVac is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00CureVac 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryXenon Pharmaceuticals and CureVac tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$714.18M$6.25B$5.28B$7.55BDividend YieldN/A3.18%5.11%4.33%P/E Ratio5.806.6821.5517.71Price / Sales1.31218.21364.7493.58Price / CashN/A65.6738.1534.64Price / Book1.285.716.293.90Net Income-$281.58M$141.32M$3.20B$247.45M7 Day Performance20.38%2.07%2.05%2.34%1 Month Performance5.98%-15.29%-10.43%-8.64%1 Year Performance9.62%-17.70%5.25%-3.88% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac3.298 of 5 stars$3.27+2.5%$10.00+205.8%+9.6%$732.09M$543.28M5.95880Earnings ReportShort Interest ↑XENEXenon Pharmaceuticals1.6654 of 5 stars$30.63+4.2%$57.38+87.3%-24.0%$2.34B$9.43M-10.86210Gap DownHigh Trading VolumeIBRXImmunityBio1.8298 of 5 stars$2.72-3.9%$12.19+348.1%-48.5%$2.32B$14.75M-2.96590Gap UpHigh Trading VolumeAMRXAmneal Pharmaceuticals3.0799 of 5 stars$7.21-2.3%$10.80+49.8%+26.4%$2.23B$2.79B-10.607,600Short Interest ↑Positive NewsGap UpMLTXMoonLake Immunotherapeutics1.7785 of 5 stars$34.78-6.5%$80.50+131.5%-20.5%$2.23BN/A-26.962Positive NewsGap UpHigh Trading VolumeTWSTTwist Bioscience3.8398 of 5 stars$36.99+2.2%$54.10+46.3%+26.6%$2.21B$330.19M-10.94990Positive NewsHigh Trading VolumeHCMHUTCHMED2.2548 of 5 stars$12.14-15.6%$19.00+56.5%-23.3%$2.12B$630.20M0.001,988Gap UpMIRMMirum Pharmaceuticals3.9569 of 5 stars$41.00-2.5%$58.20+42.0%+61.0%$2.01B$336.89M-20.30140Positive NewsVCELVericel2.333 of 5 stars$39.90-4.8%$62.29+56.1%-13.9%$2.00B$237.22M665.11300Analyst ForecastInsider TradeNews CoverageGap UpHigh Trading VolumeBHCBausch Health Companies3.9867 of 5 stars$5.26-1.4%$7.17+36.4%-50.6%$1.93B$9.63B-43.7919,900Short Interest ↑Gap UpBHVNBiohaven3.4893 of 5 stars$17.86-3.9%$62.77+251.4%-66.9%$1.82BN/A-1.91239Gap Up Remove Ads Related Companies and Tools Related Companies XENE Competitors IBRX Competitors AMRX Competitors MLTX Competitors TWST Competitors HCM Competitors MIRM Competitors VCEL Competitors BHC Competitors BHVN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
